You are here

KL2 Scholars Career Development Program

The KL2 Scholars Career Development Program is available to Assistant Professors (in rank ≤ 6 years), conducting clinical or translational research.

The program provides 75% salary support (up to $120,000 inclusive of fringe), $35,000 in research funds, and $2,000 travel funds per year, for three years.

Program overview

Available to Assistant Professors (in rank ≤ six years) conducting clinical or translational research

Provides 75% salary support (up to $120,000 inclusive of fringe), $35,000 in research funds, and $2,000 travel funds per year for 1-3 years, with the first 24 months covered by CTSI and year 3 to be covered by the AHC or scholar’s home department for Schools outside of AHC

More information

The KL2 Scholars Career Development Program is designed to develop the next generation of clinical investigators through a structured training program with a mentored, multidisciplinary clinical research emphasis. The goal is for KL2 scholars to develop successful CTS research careers with extramural funding and scholarly publications.

This three-year program aims to place junior investigators on the path to be competitive for NIH independent K- or R- awards. Success of this program will be judged by the number who go on to secure NIH independent K-awards and NIH R21 grants in the short term, and NIH R01, and R01 equivalent funding in the long term, for clinical and translational research.

Division of Biostatistics, School of Public HealthMentors: James Neaton, Jason Baker, Daniel Duprez, Dr. Cavan ReillyProject title: Integrative Omics Methods to Assess Genomic and Metabolic Influences on Subclinical CVD in HIV-Infected Men and Women

Primary mentor: Robert KaneAdditional mentors: Joseph Gaugler and William ThomasProject title: Using Facility and Resident-Level Predictors of Quality of Life in Long-Term Care to Design Successful Interventions

Primary mentor: Clifford SteerAdditional mentors: Jeffrey Albrecht, Do-Hyung Kim, and Wei-Shou HuProject title: The combination of miR-24-ASO and miR-30e-ASO as a therapeutic agent for both NAFLD and hyperlipidemia